Brendan P. Eckelman

Insider Reports History

Location
La Jolla, CA
Signature
/s/ Kelly D. Deck, Chief Financial Officer of Inhibrx Biosciences, Inc., as attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Brendan P. Eckelman:

Company Role Class Num Shares Value Price $ Report Date Ownership
Inhibrx Biosciences, Inc. Chief Scientific Officer Common Stock 433,888 $5,610,172 $12.93 29 May 2024 By the Eckelman Living Trust Dated February 5, 2014
Inhibrx Biosciences, Inc. Chief Scientific Officer Common Stock 40,000 $517,200 $12.93 29 May 2024 By trust
Inhibrx, Inc. Chief Scientific Officer Common Stock 0 $0 $30.00 30 May 2024 By the Eckelman Living Trust dated February 5, 2014
Inhibrx, Inc. Chief Scientific Officer Common Stock 0 $0 $30.00 30 May 2024 By trust
Inhibrx, Inc. Chief Scientific Officer Stock Option (right to buy) 0 $0 $34.12 30 May 2024 Direct
Inhibrx Biosciences, Inc. Chief Scientific Officer Stock Option (right to buy) 175,000 30 May 2024 Direct

Insider Reports Filed by Brendan P. Eckelman

Symbol Company Period Transactions Value $ Form Type Role Filing Time
INBX Inhibrx Biosciences, Inc. 29 May 2024 4 $0 4 Chief Scientific Officer 30 May 2024, 18:09
/report/000095014224001497-eckelman-brendan-p-2024-05-28 Inhibrx, Inc. 28 May 2024 6 -$71,956,590 4 Chief Scientific Officer 30 May 2024, 18:21
INBX Inhibrx Biosciences, Inc. 24 May 2024 0 $0 3 Chief Scientific Officer 24 May 2024, 16:46
/report/000173961424000033-eckelman-brendan-p-2024-05-22 Inhibrx, Inc. 22 May 2024 2 -$170,941 4 Chief Scientific Officer 24 May 2024, 18:15
/report/000173961424000017-eckelman-brendan-p-2024-03-13 Inhibrx, Inc. 13 Mar 2024 1 -$67,062 4 Chief Scientific Officer 15 Mar 2024, 16:48
/report/000173961424000013-eckelman-brendan-p-2024-03-08 Inhibrx, Inc. 08 Mar 2024 5 -$1,403,546 4 Chief Scientific Officer 12 Mar 2024, 18:04
/report/000173961423000016-eckelman-brendan-p-2023-03-01 Inhibrx, Inc. 01 Mar 2023 2 -$968,231 4 Chief Scientific Officer 02 Mar 2023, 15:17
/report/000173961423000012-eckelman-brendan-p-2023-02-01 Inhibrx, Inc. 01 Feb 2023 5 -$997,210 4 Chief Scientific Officer 02 Feb 2023, 18:26
/report/000173961423000006-eckelman-brendan-p-2023-01-03 Inhibrx, Inc. 03 Jan 2023 6 -$948,598 4 Chief Scientific Officer 04 Jan 2023, 16:53
/report/000173961422000128-eckelman-brendan-p-2022-12-06 Inhibrx, Inc. 06 Dec 2022 3 -$1,088,683 4 Chief Scientific Officer 07 Dec 2022, 15:30
/report/000173961422000114-eckelman-brendan-p-2022-11-01 Inhibrx, Inc. 01 Nov 2022 2 -$1,340,387 4 Chief Scientific Officer 02 Nov 2022, 17:04
/report/000173961422000105-eckelman-brendan-p-2022-10-04 Inhibrx, Inc. 04 Oct 2022 7 -$1,112,813 4 Chief Scientific Officer 05 Oct 2022, 16:15
/report/000173961422000097-eckelman-brendan-p-2022-09-13 Inhibrx, Inc. 13 Sep 2022 3 $0 4 Chief Scientific Officer 14 Sep 2022, 16:09
/report/000173961422000095-eckelman-brendan-p-2022-09-06 Inhibrx, Inc. 06 Sep 2022 2 -$596,274 4 Chief Scientific Officer 07 Sep 2022, 16:57
/report/000173961422000077-eckelman-brendan-p-2022-08-02 Inhibrx, Inc. 02 Aug 2022 2 -$719,835 4 Chief Scientific Officer 04 Aug 2022, 16:33
/report/000173961422000073-eckelman-brendan-p-2022-07-07 Inhibrx, Inc. 07 Jul 2022 1 -$686,800 4 Chief Scientific Officer 08 Jul 2022, 16:03
/report/000173961422000039-eckelman-brendan-p-2022-04-05 Inhibrx, Inc. 05 Apr 2022 1 -$10,016 4 Chief Scientific Officer 07 Apr 2022, 16:11